In our coverage of biotechnology this week, analyst Liisa Bayko talks about her concerns in the Biotechnology Sector:
TWST: Are there any names that worry you?
Ms. Bayko: I think Dendreon is a little bit of a worry because it’s so volatile.It’s trading up now, and I have a sell rating on it. They are in the prostate cancer space. Their ongoing trial is called IMPACT, and we are going to have the data from that the middle of the next year. I worry if that’s going to be positive. They are putting so much into making that positive, that’s my concern. If it’s not positive, then what?
For our full coverage of the Biotech sector, featuring interviews with CEOs from 20 different companies, click here.